Inhibrx (NASDAQ:INBX) Coverage Initiated at JMP Securities

JMP Securities began coverage on shares of Inhibrx (NASDAQ:INBX) in a report published on Tuesday, MarketBeat Ratings reports. The brokerage issued a market perform rating on the stock.

Inhibrx Stock Down 0.1 %

INBX opened at $13.43 on Tuesday. Inhibrx has a 52 week low of $12.61 and a 52 week high of $18.95. The business’s 50 day moving average is $18.57 and its two-hundred day moving average is $29.75.

Insiders Place Their Bets

In other news, Director Jon Faiz Kayyem purchased 57,549 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were bought at an average price of $17.32 per share, with a total value of $996,748.68. Following the completion of the transaction, the director now directly owns 1,150,410 shares in the company, valued at approximately $19,925,101.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Jon Faiz Kayyem bought 57,549 shares of the stock in a transaction on Wednesday, June 5th. The shares were bought at an average cost of $17.32 per share, for a total transaction of $996,748.68. Following the purchase, the director now owns 1,150,410 shares of the company’s stock, valued at approximately $19,925,101.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Brendan P. Eckelman sold 300,000 shares of Inhibrx stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.30, for a total value of $10,290,000.00. Following the completion of the transaction, the insider now owns 1,735,553 shares in the company, valued at $59,529,467.90. The disclosure for this sale can be found here. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. E Fund Management Co. Ltd. purchased a new position in shares of Inhibrx in the 4th quarter valued at approximately $209,000. Wellington Management Group LLP grew its stake in shares of Inhibrx by 24.4% in the 3rd quarter. Wellington Management Group LLP now owns 174,899 shares of the company’s stock valued at $3,209,000 after purchasing an additional 34,310 shares during the last quarter. AJOVista LLC purchased a new stake in shares of Inhibrx in the fourth quarter valued at approximately $26,000. Signaturefd LLC boosted its stake in shares of Inhibrx by 4,637.5% in the fourth quarter. Signaturefd LLC now owns 758 shares of the company’s stock valued at $29,000 after buying an additional 742 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Inhibrx in the fourth quarter valued at approximately $58,140,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.